

A Case of Orbital Solitary Fibrous Tumor

Hiroshi Takamura,* Makoto Kanno,* Hidetoshi Yamashita* and Kunihiko Maeda[†]

*Department of Ophthalmology; [†]First Department of Pathology, Yamagata University School of Medicine, Yamagata, Japan

Background: Solitary fibrous tumor is a spindle cell neoplasm that most commonly arises in the pleura and very rarely involves the orbit.

Case: A 38-year-old woman presented with slowly progressive proptosis of 3 months duration and optic nerve head edema in her right eye. Magnetic resonance imaging revealed a well-circumscribed, round mass lesion, which showed isointensity to the gray matter in a T1-weighted image, and variegated intensity in a T2-weighted image and contact with the optic nerve in her right orbit. The tumor was successfully removed by anterior orbitotomy.

Observations: The tumor showed a "patternless pattern" of tumor cell arrangement, alternating hypercellular and hypocellular areas, a hemangiopericytoma-like pattern, and thickened strands of collagen. Immunohistochemically, the tumor cells were positive for CD34 and vimentin, and all were negative for other markers of epithelial, neural, muscular, histiocytic, and vascular endothelial cell elements. The tumor was diagnosed as a solitary fibrous tumor, and the patient was doing well with no evidence of recurrence 15 months after surgery.

Conclusions: This case was the 19th reported case of solitary fibrous tumor in the orbital region. CD34 is a highly sensitive marker for solitary fibrous tumor. **Jpn J Ophthalmol 2001;45:412–419** © 2001 Japanese Ophthalmological Society

Key Words: Histopathological study, immunohistochemical study, magnetic resonance imaging, orbital tumor, solitary fibrous tumor.

Introduction

Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm in adults. It most commonly arises in the pleura,¹⁻⁴ but recently has been described in extrapleural sites, such as the peritoneum,^{5,6} lung,^{3,5,7} pericardium,⁸ mediastinum,^{9,10} periosteum,¹¹ liver,¹² thyroid glands,¹³ parotid glands,¹⁴ upper respiratory tract,^{15–17} paranasal sinuses,¹⁶ intracranial meninges,¹⁸ and orbit.^{19–31} We report a rare case of orbital SFT. To diagnose SFT, researchers have utilized the pathological findings of a short fascicular, storiform, or haphazard arrangement of spindle cells exhibiting the so-called "patternless pattern," alternating hypercellular and hypocellular areas, a hemangiopericytoma-like pattern of vascularity, and stromal thickened strands of collagen.^{1–31} However, there are only a few pathological tumor markers for SFT. Solitary fibrous tumor is characterized by its consistently strong immunoreactivity to the antigen CD34.^{14,18,20–31} CD34 is initially a hematopoietic progenitor cell antigen, and recently has been detected in endothelial cells and vascular neoplasms as well as in primitive mesenchymal cells, mesenchymal spindle cell tumors, and certain connective tissue cells in the skin.^{20,24,25,32}

To our knowledge, there have been only 18 cases of SFT reported in the orbital region.^{19–31} We report the 19th case with the findings of magnetic resonance imaging (MRI), histopathological, and immunohistochemical studies.

Case Report

A 38-year-old Japanese woman with a 3-month history of proptosis in the right eye was referred to the Yamagata University Hospital on November 5, 1998. She had no history of trauma or sinusitis, and

Received: April 21, 2000

Correspondence and reprint requests to: Hiroshi TAKAMURA, MD, Department of Ophthalmology, Yamagata University School of Medicine, 2-2-2, Iidanishi, Yamagata City 990-9585, Japan

complained of no pain or vision changes. Ophthalmological examination showed that her visual acuity was RE: 1.2 and LE: 1.5. Intraocular pressure was normal in both eyes (15 mm Hg in the right eye, 16 mm Hg in the left eye). Exophthalmometry measured 17 mm in the right eye and 13 mm in the left eye (Figure 1). Ocular movement was normal. A solid mass was palpable on her right orbital medialsuperior margin. The conjunctiva was not hyperemic or edematous. Pupils were symmetric, round, and reactive with no evidence of a relative afferent pupillary defect. Fundus examination with indirect ophthalmoscopy showed congestion of the optic nerve head associated with linear hemorrhage, but no choroidal folds in the right eye (Figure 2). A Goldmann visual field analyzer revealed enlargement of the Marriott scotoma and a depression in the temporal inferior site of her right eye. Critical fusion frequency used to examine the optic nerve function was 43 Hz in both eyes.

A computed tomography (CT) scan revealed a sharply defined soft tissue density mass, which was





Figure 1. (top) and (bottom). Proptosis is observed in right eye.

uniformly well-enhanced in the retrobulbar and medial sides of the right orbit. There was no evidence of calcification or bone destruction (Figure 3). Magnetic resonance imaging showed that a well-circumscribed, round mass had contact with the optic nerve. The lesion showed isointensity to the gray matter in a T1-weighted image, and iso- and hypointensity in the central area, and hyperintensity at the tumor's edge in a T2-weighted image. The lesion revealed good homogeneous enhancement on postcontrast using a gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) T1-weighted image (Figure 4). There were no systemic abnormalities.

The patient underwent excision of the lesion by anterior orbitotomy. As the tumor lay in the orbital fatty tissue and did not adhere to the adjacent structures, it could be totally excised. There was no evidence during the operation that the tumor had adhered to or invaded the optic nerve.

Postoperative visual acuity and ocular movement remained intact. Proptosis and optic disk edema of her right eye fully resolved. Visual field abnormalities, including enlargement of the Marriott scotoma and a depression in the temporal inferior site of her right eye, also resolved completely. Fifteen months after surgery, the patient was doing well with no evidence of recurrence.

Histological Examination/Materials and Methods

The surgical specimen was fixed in 10% buffered formaldehyde and embedded in paraffin. The tissue sections were stained with hematoxylin-eosin and examined by light microscopy. Immunohistochemical studies were performed on the formaldehydefixed paraffin-embedded tissues by the peroxidaseantiperoxidase technique, using antibodies to CD34, vimentin, S-100 protein, cytokeratin, desmin, smooth muscle actin, Factor VIII, and α -antichymotrypsin.

Results

Gross Pathology

The tumor was well-circumscribed and appeared encapsulated, elastic hard, and reddish in color. It had a solid appearance and pinkish-white color at the cut surface. It measured $22 \times 15 \times 15$ mm (Figure 5).

Microscopic Pathology

Sections of the tumor showed alternating hypercellular and hypocellular areas. The hypercellular area was composed of spindle cells that were arranged haphazardly or in part were arranged in a storiform pattern



Figure 2. (left) Right eye. Optic nerve head is congested, and associated with linear hemorrhage at inferior edge (right) Left eye. No abnormal findings.

with short interlacing fascicles (Figure 6A). The hypocellular area was a less cellular sclerotic region in which tumor cells were interspersed with dense bundles of collagen (Figure 6 top right). In part, tumor cells were seen around dilated staghorn-shaped vessels, creating a hemangiopericytoma-like pattern (Figure 6 bottom left). The tumor cells had uniform, oval, vesicular nuclei with finely dispersed chromatin and inconspicuous



Figure 3. Axial view by orbital computed tomography, (left) not enhanced, (right) contrast enhanced. Well-circumscribed, soft tissue density mass was seen in retrobulbar and medial sides of right orbit. Lesion was uniformly well-enhanced.

H. TAKAMURA ET AL. ORBITAL SOLITARY FIBROUS TUMOR







Figure 4. Coronal view by orbital magnetic resonance imaging, **(top left)** T1-weighted image, **(top right)** T2-weighted image, **(bottom)** postcontrast by gadolinium diethylenetriamine pentaacetic acid T1-weighted image. Lesion shows isointensity to gray matter in T1-weighted image, and isoand hypointensity in central area, and hyperintensity at tumor's edge in T2-weighted image. Lesion shows homogeneous enhancement. Lesion is in contact with optic nerve (Arrow).





Figure 5. (left) Tumor was encapsulated, elastic hard, and reddish in color. (right) Solid appearance and pinkish-white color at cut surface.



Figure 6. Microscopic findings with hematoxylin-eosin staining. (**top left**) Hypercellular area: many spindle cells are arranged haphazardly. Bar = $100 \mu m$; (**top right**) Hypocellular area: tumor cells are interspersed with dense bundles of collagen. Bar = $100 \mu m$; (**bottom left**) Dilated staghorn-shaped vessels are creating hemangiopericytoma-like pattern. Bar = $100 \mu m$. (**bottom right**) Tumor cells have oval, vesicular nuclei with finely dispersed chromatin and inconspicuous nucleoli. Bar = $25 \mu m$.

nucleoli. Mitotic count was low and areas of necrosis or hemorrhage were not seen (Figure 6 bottom right).

Immunohistochemically, the tumor cells were strongly positive for CD34 and vimentin. They were uniformly negative for S-100 protein, cytokeratin, desmin, smooth muscle actin, Factor VIII, and α -1-antichymotrypsin. These immunohistochemical findings are typical of SFT (Figure 7).

Discussion

Diagnosis

Solitary fibrous tumor was first described as a localized fibrous mesothelioma in the pleura by Klemperer and Rabin in 1931.¹ It was once thought to be of mesothelial origin and was called benign or localized fibrous mesothelioma.^{1,3,6,7,8,12} However, evidence of mesothelial differentiation has not been found by light microscopy or electron microscopy, or in the consistent negative immunoreactivity of epithelial markers, or in the subsequent identification of this tumor in extrapleural sites not usually associated with serosal surfaces, including the thyroid glands,¹³ parotid glands,¹⁴ nasal cavity,^{16,17,22} and paranasal sinuses.¹⁶ This supports a mesenchymal, possibly fibroblastic/myofibroblastic origin for SFT.^{3–8,10,11,13,14,16–28,30}

The classic histologic features of SFT are a short fascicular, storiform, or haphazard arrangement of spindle cells exhibiting the so-called "patternless pattern," alternating hypercellular and hypocellular areas, a hemangiopericytoma-like pattern of vascularity, and stromal thickened strands of collagen.^{1–31} In addition, synovial sarcoma-like areas and neuraltype palisades have been described.² The present case showed these typical histologic features of SFT, including the "patternless pattern" of tumor cell arrangement, alternating hypercellular and hypocellular areas, a hemangiopericytoma-like pattern, and thickened strands of collagen.



Figure 7. Immunohistochemical findings: Tumor cells are strongly positive for (top) CD34 and (middle) vimentin, and negative for (bottom) S-100 protein. Bars = $50 \mu m$.

Immunohistochemical Observation

Immunohistochemically, the tumor cells have been reported to express a strong diffuse immunoreactivity to CD34 antigen.^{14,18,20–31} In addition, vimentin (a marker of mesenchymal origin)^{2,3,5–17,19,21–25,27,28,30,31} is usually positive, and KP-1 (a marker of mesenchymal

and histiocytic elements: CD68) is occasionally positive.²¹ Immunohistochemical staining is negative for epithelial markers (cytokeratin,^{2,3,5–19,21–23,25,27} epithelial membrane antigen, ^{2,3,5,7,11,12,15,18,19,21–23,25,27,28,30} carcinoembryonic antigen),^{3,9,22} neural markers (S-100 protein,^{2,3,5,7,10,11,13-19,21-23,25,27-31} glial fibrillary acidic protein,^{19,22,27} Leu-7,¹⁹ neurofilament),^{3,13,16,19,22} muscle element markers (desmin,^{2,5–7,11–16,18,21–24,27} smooth muscle actin,^{14,18,21,22,28,30} muscle-specific actin,^{14,21-} ^{23,30} myoglobin,²² actin),^{2,6,15–17,25} histiocytic markers $(\alpha$ -1-antitrypsin,^{13,19} α -1-antichymotrypsin),^{13,19,30} and vascular endothelial cell markers (Factor VIII).^{3,6,19,22,30} The present case showed that CD34 antigen and vimentin were positive, and other markers of the epithelial element, neural element, muscular element, histiocytic element, and vascular endothelial cell element were all negative.

CD34 monoclonal antibodies recognize a singlechain transmembrane glycoprotein of 115 kDa. CD34 antigen is selectively expressed in human hemopoietic progenitor cells and the vascular endothelium.³² The diagnostic utility of CD34 immunoreactivity is not limited to leukemia or vascular neoplasms, but includes primitive mesenchymal cells, mesenchymal spindle cell tumors, and tumors of the outer root sheath of hair follicles.^{20,24} Westra et al²⁰ described that SFT and dermatofibrosarcoma protuberans demonstrated a strong and generalized CD34 positivity; in contrast, neurofibroma, schwannoma, and hemangiopericytoma showed weak positivity for CD34. CD34 immunoreactivity was not observed in mesothelioma, synovial sarcoma, fibrosarcoma, and spindle-cell thymoma. This evidence suggests that SFT may arise from primitive mesenchymal cells and that CD34 immunoreactivity can be a highly sensitive marker of SFT.

Differential Diagnosis

Because SFT has a variety of morphological patterns that overlap with those of other spindle cell tumors, and because a wide range of mesenchymal tumors can occur in the orbit, the differential diagnosis of orbital SFT includes fibrous histiocytoma, rare fibroblastic tumors, as well as other uncommon spindle cell tumors such as hemangiopericytoma, meningioma, and nerve sheath tumors. Fibrous histiocytoma, which is the most common mesenchymal orbital tumor in adults, is composed of fibroblastic and histiocytic cells including histiocyte-like giant cells, and typically shows a uniform storiform pattern.^{19,21,25,30} In SFT, there may be a focal storiform pattern but it is not present throughout the tumor, and histiocytelike giant cells are not seen.^{19,30} Other benign fibrous tumors of the orbit, such as fibromatosis, show homogeneous, dense collagenous fibrous tissues with minimum vascularity and without a storiform pattern.¹⁹ Fibromatosis has an infiltrative nature that is different from the circumscribed nature of SFT.²¹ Hemangiopericytoma is composed of oval to fusiform cells, characteristically surrounding variably sized branching, so-called "staghorn-shaped" vessels.^{19,33} In hemangiopericytoma, abundant stromal banded collagen is rarely seen,^{19,21,22} and CD34 immunoreactivity is weaker than in SFT. In meningioma of the orbit, tumor cells are arranged in nests, whorls, commonly with psammoma bodies. Particularly in fibroblastic meningioma, a storiform pattern is prominent. Tumor cells in meningioma are immunoreactive for EMA and keratin proteins,19,30 markers which are usually negative in SFT. Schwannoma of the orbit has Antoni A (palisading pattern and Verocay bodies) and Antoni B areas, and unlike SFT, these tumor cells are immunoreactive to nerve sheath differentiation markers, such as S-100 protein.19,21,22,24,30

Recently, giant cell angiofibroma, because of its morphological features with a richly vascularized and patternless proliferation of spindle-shaped cells and its immunoreactivity to CD34 and vimentin, has been reported to most closely resemble SFT.³⁴ However, giant cell angiofibroma has multinucleated giant cells and pseudovascular spaces which are not features of SFT. Moreover, giant cell angiofibroma is mainly lo-

cated in the eyelid in contrast to SFT, which is likely to be situated in a deeper portion of the orbit.

Comparison with Previous Cases

Eighteen cases of orbital SFT have been described (Table 1).^{19–31} The ages of the patients ranged from 19 to 76 years. Eight cases were men and 10 were women. The clinical sign in 12 of the 18 cases was proptosis. The prominent location of the tumor was on the medial site of the orbit. Expression of CD34 and vimentin was seen in all cases that were examinated for these markers. Treatment in all cases was surgical excision. Twelve cases had no evidence of recurrence. Only 1 case has documented recurrence and this recurrence happened twice.¹⁹

The MRI findings of SFT described that the mass lesion was isointense or hypointense to gray matter in a T1-weighted image.^{11,18,23,27,29,31} In a T2-weighted image, the lesion showed hypointensity,²³ or hyperintensity,²⁷ or variegated intensity.^{11,29,31} Using Gd-DTPA, the lesion showed homogeneous enhancement,^{18,27,29} or variable enhancement with central areas of less enhancement.^{23,31} In the current case, the mass lesion had isointensity to the gray matter in T1, variegated intensity in a T2-weighted image and homogeneous enhancement. The variable findings of MRI were considered to be due to the tumor's diversified pathological components including cellularity, rich collagenous fibers, and vascularity in the hemangiopericytoma-like pattern.

Table 1. Summary of Clinical Findings of Orbital Solitary Fibrous Tumor

Age				Size of Tumor	Immunoreactivity			
(year)	Sex	Presentation	Laterality Location	(mm)	CD34	Vimentin	Treatment	Outcome
44	Male	Proptosis	Right, medial	30	ND	+	Excision	NED. 18 months
65	Female	Proptosis	Left, medial	15	ND	+	Excision	NED, 12 years
69	Female	Proptosis	Right	15	ND	+	Excision	Recurrence at 4 and 6 years
60	Male	Orbital mass	NR	NR	+	ND	NR	NR
63	Female	Orbital mass	NR	NR	+	ND	NR	NR
40	Female	Proptosis	Left, superolateral	32×26×15	+	+	Excision	NED, 18 months
20	Female	Tumor palpable	Left, anteromedial	30×20×20	+	+	Excision	NED, 23 months
19	Female	Tumor palpable	Right, lower anterior	25×13×10	+	+	Excision	NED, 6 years
21	Male	Proptosis	Left, medial	45×20×20	+	+	Excision	NED, 22 months
75	Male	Proptosis	Left, retrobulbar	NR	+	+	Excision	NED, 1 month
43	Female	Proptosis	Left, superolateral	40×30×20	+	+	Excision	NED
76	Male	Proptosis	Left, superolateral	15	+	+	Excision	NED, 1 year
48	Female	Proptosis	Left, superomedial	35	+	ND	Excision	NR
23	Male	Proptosis	Right, superomedial	25	+	+	Excision	NED, 9 months
23	Female	Palpebral swelling	Left, medial	22×13×10	+	+	Excision	NR
32	Female	Proptosis	Left, lateral	20×15×8	+	ND	Excision	NR
48	Male	Proptosis	Left, medial	35×30×25	+	+	Excision	NED
27	Male	Tumor palpable	Right, medial	19×19	+	+	Excision	NED, 3 months
38	Female	Proptosis	Right, medial	22×15×15	+	+	Excision	NED, 15 months
	Age (year) 44 65 69 60 63 40 20 19 21 75 43 76 48 23 23 32 48 27 38	Age (year)Sex44Male65Female69Female60Male63Female40Female20Female20Female21Male75Male43Female23Female23Female32Female38Female	Age (year)SexPresentation44MaleProptosis65FemaleProptosis69FemaleProptosis60MaleOrbital mass63FemaleOrbital mass63FemaleProptosis20FemaleTumor palpable19FemaleTumor palpable21MaleProptosis75MaleProptosis76MaleProptosis23FemaleProptosis23FemaleProptosis23FemaleProptosis23FemaleProptosis23FemaleProptosis24FemaleProptosis25FemaleProptosis26FemaleProptosis27MaleTumor palpable38FemaleProptosis	Age (year)SexPresentationLaterality Location44MaleProptosisRight, medial65FemaleProptosisLeft, medial69FemaleProptosisRight60MaleOrbital massNR63FemaleOrbital massNR40FemaleProptosisLeft, superolateral20FemaleTumor palpableLeft, anteromedial19FemaleTumor palpableRight, lower anterior21MaleProptosisLeft, retrobulbar43FemaleProptosisLeft, superolateral76MaleProptosisLeft, superolateral48FemaleProptosisLeft, superomedial23MaleProptosisLeft, superomedial24FemaleProptosisLeft, medial25MaleProptosisLeft, superomedial26FemaleProptosisLeft, superomedial76MaleProptosisLeft, superomedial23FemaleProptosisLeft, medial32FemaleProptosisLeft, medial33FemaleProptosisLeft, medial34MaleProptosisLeft, medial35FemaleProptosisLeft, medial36FemaleProptosisRight, medial38FemaleProptosisRight, medial	Age (year)Size of Tumor (mm)44MaleProptosisRight, medial3065FemaleProptosisLeft, medial1569FemaleProptosisRight1560MaleOrbital massNRNR63FemaleOrbital massNRNR40FemaleProptosisLeft, superolateral $32 \times 26 \times 15$ 20FemaleTumor palpableLeft, anteromedial $30 \times 20 \times 20$ 19FemaleTumor palpableRight, lower anterior $25 \times 13 \times 10$ 21MaleProptosisLeft, retrobulbarNR43FemaleProptosisLeft, superolateral $35 \times 20 \times 20$ 75MaleProptosisLeft, superolateral $40 \times 30 \times 20$ 76MaleProptosisLeft, superolateral 15 48FemaleProptosisLeft, superomedial 35 23MaleProptosisLeft, medial $22 \times 13 \times 10$ 32FemalePalpebral swellingLeft, medial $22 \times 13 \times 10$ 32FemaleProptosisLeft, medial $35 \times 30 \times 25$ 27MaleTumor palpableRight, medial 19×19 38FemaleProptosisRight, medial $22 \times 15 \times 15$	Age (year)SexPresentationLaterality LocationSize of Tumor (mm)Immun $CD34$ 44MaleProptosisRight, medial30ND65FemaleProptosisLeft, medial15ND69FemaleProptosisRight15ND60MaleOrbital massNRNR+63FemaleOrbital massNRNR+40FemaleProptosisLeft, superolateral $32 \times 26 \times 15$ +20FemaleTumor palpableLeft, anteromedial $30 \times 20 \times 20$ +19FemaleTumor palpableRight, lower anterior $25 \times 13 \times 10$ +21MaleProptosisLeft, medial $45 \times 20 \times 20$ +75MaleProptosisLeft, superolateral $30 \times 30 \times 20$ +76MaleProptosisLeft, superolateral 15 +48FemaleProptosisLeft, superolateral 35 +23MaleProptosisLeft, superomedial 35 +23FemaleProptosisLeft, medial $22 \times 13 \times 10$ +32FemaleProptosisLeft, medial $35 \times 30 \times 25$ +24MaleProptosisLeft, medial $35 \times 30 \times 25$ +27MaleTumor palpableRight, medial 19×19 +38FemaleProptosisRight, medial 19×19 +38Female <td>Age (year)Size of Tumor SexImmunoreactivity PresentationImmunoreactivity CD34Immunoreactivity CD3444MaleProptosisRight, medial30ND+65FemaleProptosisLeft, medial15ND+69FemaleProptosisRight15ND+60MaleOrbital massNRNR+ND63FemaleOrbital massNRNR+ND40FemaleProptosisLeft, superolateral$32 \times 26 \times 15$++20FemaleTumor palpableLeft, anteromedial$30 \times 20 \times 20$++19FemaleTumor palpableRight, lower anterior$25 \times 13 \times 10$++21MaleProptosisLeft, superolateral$45 \times 20 \times 20$++43FemaleProptosisLeft, nectial$40 \times 30 \times 20$++43FemaleProptosisLeft, superolateral15++48FemaleProptosisLeft, superomedial35+ND23MaleProptosisLeft, medial$22 \times 13 \times 10$++32FemaleProptosisLeft, medial$20 \times 15 \times 8$+ND48MaleProptosisLeft, medial$35 \times 30 \times 25$++48MaleProptosisLeft, medial19×19++38FemaleProptosis<td< td=""><td>Age (year)SexPresentationLaterality LocationSize of Tumor (mm)Immuoreactivity $CD34$Treatment44MaleProptosisRight, medial30ND+Excision65FemaleProptosisLeft, medial15ND+Excision69FemaleProptosisRight15ND+Excision60MaleOrbital massNRNR+NDNR63FemaleOrbital massNRNR+Excision20FemaleProptosisLeft, superolateral$32 \times 26 \times 15$++Excision20FemaleTumor palpableLeft, anteromedial$30 \times 20 \times 20$++Excision20FemaleTumor palpableRight, lower anterior$25 \times 13 \times 10$++Excision21MaleProptosisLeft, medial$45 \times 20 \times 20$++Excision21MaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision23FemaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision33FemaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision44MaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision34FemaleProptosisLeft, superolateral35×1++Excision33Male<!--</td--></td></td<></td>	Age (year)Size of Tumor SexImmunoreactivity PresentationImmunoreactivity CD34Immunoreactivity CD3444MaleProptosisRight, medial30ND+65FemaleProptosisLeft, medial15ND+69FemaleProptosisRight15ND+60MaleOrbital massNRNR+ND63FemaleOrbital massNRNR+ND40FemaleProptosisLeft, superolateral $32 \times 26 \times 15$ ++20FemaleTumor palpableLeft, anteromedial $30 \times 20 \times 20$ ++19FemaleTumor palpableRight, lower anterior $25 \times 13 \times 10$ ++21MaleProptosisLeft, superolateral $45 \times 20 \times 20$ ++43FemaleProptosisLeft, nectial $40 \times 30 \times 20$ ++43FemaleProptosisLeft, superolateral 15 ++48FemaleProptosisLeft, superomedial 35 +ND23MaleProptosisLeft, medial $22 \times 13 \times 10$ ++32FemaleProptosisLeft, medial $20 \times 15 \times 8$ +ND48MaleProptosisLeft, medial $35 \times 30 \times 25$ ++48MaleProptosisLeft, medial 19×19 ++38FemaleProptosis <td< td=""><td>Age (year)SexPresentationLaterality LocationSize of Tumor (mm)Immuoreactivity $CD34$Treatment44MaleProptosisRight, medial30ND+Excision65FemaleProptosisLeft, medial15ND+Excision69FemaleProptosisRight15ND+Excision60MaleOrbital massNRNR+NDNR63FemaleOrbital massNRNR+Excision20FemaleProptosisLeft, superolateral$32 \times 26 \times 15$++Excision20FemaleTumor palpableLeft, anteromedial$30 \times 20 \times 20$++Excision20FemaleTumor palpableRight, lower anterior$25 \times 13 \times 10$++Excision21MaleProptosisLeft, medial$45 \times 20 \times 20$++Excision21MaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision23FemaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision33FemaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision44MaleProptosisLeft, superolateral$40 \times 30 \times 20$++Excision34FemaleProptosisLeft, superolateral35×1++Excision33Male<!--</td--></td></td<>	Age (year)SexPresentationLaterality LocationSize of Tumor (mm)Immuoreactivity $CD34$ Treatment44MaleProptosisRight, medial30ND+Excision65FemaleProptosisLeft, medial15ND+Excision69FemaleProptosisRight15ND+Excision60MaleOrbital massNRNR+NDNR63FemaleOrbital massNRNR+Excision20FemaleProptosisLeft, superolateral $32 \times 26 \times 15$ ++Excision20FemaleTumor palpableLeft, anteromedial $30 \times 20 \times 20$ ++Excision20FemaleTumor palpableRight, lower anterior $25 \times 13 \times 10$ ++Excision21MaleProptosisLeft, medial $45 \times 20 \times 20$ ++Excision21MaleProptosisLeft, superolateral $40 \times 30 \times 20$ ++Excision23FemaleProptosisLeft, superolateral $40 \times 30 \times 20$ ++Excision33FemaleProptosisLeft, superolateral $40 \times 30 \times 20$ ++Excision44MaleProptosisLeft, superolateral $40 \times 30 \times 20$ ++Excision34FemaleProptosisLeft, superolateral 35×1 ++Excision33Male </td

ND: not done, NED: no evidence of disease, NR: not reported.

Orbital SFT generally pursues a benign, nonaggressive course and is usually cured by simple excision,^{19–31} which is similar to SFT in other sites. It is reported that 13–23% of SFT in the pleura have a tendency to behave in an aggressive manner.^{3,21} It is also reported that tumors with aggressive histopathological features, including hypercellularity, high mitotic counts (at least four mitoses/10 high-power fields), and cellular pleomorphism, and with the macroscopic findings of tumor necrosis and large tumor size, are likely to manifest invasion of adjacent tissue, recurrence, or distant metastases.^{19,22,24–26,28,30} Although the present case has been free from recurrence for 15 months after operation, careful follow-up is mandatory.

This work was supported in part by Grant-in-Aid no. 11877297, 13671819 from the Ministry of Education, Science, Sports and Culture of Japan, Yamagata Prefecture and Suzuken Memorial Foundation.

References

- 1. Klemperer P, Rabin CB. Primary neoplasms of the pleura: a report of five cases. Arch Pathol 1931;11:385–412.
- Moran CA, Suster S, Koss MN. The spectrum of histologic growth pattern in benign and malignant fibrous tumors of the pleura. Semin Diagn Pathol. 1992;9:169–80.
- England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol 1989;13:640–58.
- Dalton WT, Zolliker AS, McCaughey WTE, Jacques J, Kannerstein M. Localized primary tumors of pleura: an analysis of 40 cases. Cancer 1979;44:1465–75.
- Goodlad JR, Fletcher CD. Solitary fibrous tumor arising at unusual sites: analysis of a series. Histopathology 1991;19:515–22.
- Young RH, Clement PB, McCaughey WTE. Solitary fibrous tumors ('fibrous mesotheliomas') of the peritoneum. Arch Pathol Lab Med 1990;114:493–5.
- Yousem SA, Flynn SD. Intrapulmonary localized fibrous tumor: intraparenchymal so-called localized fibrous mesothelioma. Am J Clin Pathol 1988;89:365–9.
- El-Naggar AK, Ro JY, Ayala AG, Ward R, Ordonez NG. Localized fibrous tumor of the serosal cavities: immunohistochemical, electron microscopic, and flow-cytometric DNA study. Am J Clin Pathol 1989;92:561–5.
- Weinder N. Solitary fibrous tumor of the mediastinum. Ultrastruct Pathol 1991;15:489–92.
- Witkin GB, Rosai J. Solitary fibrous tumor of the mediastinum: a report of 14 cases. Am J Surg Pathol 1989;13:547–57.
- O'Connell JX, Logan PM, Beauchamp CP. Solitary fibrous tumor of the periosteum. Hum Pathol 1995;26:460–2.
- Kottke-Marchant K, Hart WR, Broughan T. Localized fibrous tumor (localized fibrous mesothelioma) of the liver. Cancer 1989;64:1096–102.
- Taccagni G, Sambade C, Nesland J, Terreni MR, Sobrino-Simoes M. Solitary fibrous tumor of the thyroid: clinicopathological, immunohistochemical and ultrastructual study of

three cases. Virchows Arch A Pathol Anat Histopathol 1993; 422:491–7.

- Hanau CA, Miettinen M. Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol 1995; 26:440–9.
- Safneck JR, Alguacil-Garcia A, Sort JC, Phillips SM. Solitary fibrous tumor: report of two new locations in the upper respiratory tract. J Laryngol Otol 1993;107:252–6.
- Zukerberg LR, Rosenberg AE, Randolph G, Pilch BZ, Goodman ML. Solitary fibrous tumor of the nasal cavity and paranasal sinuses. Am J Surg Pathol 1991;15:126–30.
- 17. Witkin GB, Rosai J. Solitary fibrous tumor of the upper respiratory tract: a report of six cases. Am J Surg Pathol 1991;15: 842-8.
- Carneiro SS, Scheithauer BW, Nascimento AG, Hirose T, Davis DH. Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma: a clinicopathologic and immunohistochemical study. Am J Clin Pathol 1996;106:217–24.
- Dorfman DM, To K, Dickersin GR, Rosenberg AE, Pilch BZ. Solitary fibrous tumor of the orbit. Am J Surg Pathol 1994;18:281–6.
- Westra WH, Gerald WL, Rosai J. Solitary fibrous tumor. Consistent CD34 immunoreactivity and occurrence in the orbit. Am J Surg Pathol 1994;18:992–8.
- Lucas DR, Campbell RJ, Fletcher CDM, Garrity JA, Nascimento AG, McCartney ACE. Solitary fibrous tumor of the orbit. Int J Surg Pathol 1995;2:193–8.
- Fukunaga M, Ushigome S, Nomura K, Ishikawa E. Solitary fibrous tumor of the nasal cavity and orbit. Pathol Int 1995; 45:952–7.
- DeBacker CM, Bodker F, Putterman AM, Beckmann E. Solitary fibrous tumor of the orbit. Am J Ophthalmol 1996;121: 447–9.
- Ramdial PK, Nadvi S. An unusual cause of proptosis: orbital solitary fibrous tumor: case report. Neurosurgery 1996;38: 1040–3.
- Scott IU, Tanenbaum M, Rubin D, Lores E. Solitary fibrous tumor of the lacrimal gland fossa. Ophthalmology 1996; 103:1613–8.
- Ruska KM, Westra WH. Pathologic quiz case 1. Solitary fibrous tumor (SFT) of the orbit. Arch Otolaryngol Head Neck Surg 1996;122:1130–2.
- Sciot R, Goffin J, Fossion E, Wilms G, Dom R. Solitary fibrous tumor of the orbit. Histopathology 1996;28:188–91.
- McElvanny AM, Noble JL, O'Donovan DG, Bonshek RE, Banerjee SS. Solitary fibrous tumor: an atypical presentation within the orbit [letter]. Eye 1996;10:396–9.
- 29. Char D, Weidner N, Ahn J, Harbour JW. Solitary fibrous tumor of the orbit. Orbit 1997;16:113–8.
- 30. Miyagi N, Sugita Y, Terasaki M, et al. Solitary fibrous tumor of the orbit: a case report. Jpn J Neurosurg 1998;7:243–7.
- Nakamura Y, Ohtsuka K, Hashimoto M, Ichimiya S, Sato M. A case of solitary fibrous tumor of the orbit. Rinsho Ganka (Jpn J Clin Ophthalmol) 1999;53:1381–4.
- 32. Katz FE, Tindle RW, Sutherland DR, Greaves MF. Identification of a membrane glycoprotein associated with hemopoietic progenitor cells. Leuk Res 1985;9:191–8.
- Takamura H, Takahashi S. Two cases of orbital hemangiopericytoma. Ganka Rinsho Iho (Jpn Rev Clin Ophthalmol) 1999;93:44–9.
- Hayashi N, Borodic G, Karesh JW, et al. Giant cell angiofibroma of the orbit and eyelid. Ophthalmology 1999;106:1223–9.